Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

5.89 (USD) • At close January 14, 2025
Bedrijfsnaam Iovance Biotherapeutics, Inc.
Symbool IOVA
Munteenheid USD
Prijs 5.89
Beurswaarde 1,795,160,090
Dividendpercentage 0%
52-weken bereik 5.77 - 18.33
Industrie Biotechnology
Sector Healthcare
CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Website https://www.iovance.com

An error occurred while fetching data.

Over Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma;

Vergelijkbare Aandelen

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Insmed Incorporated logo

Insmed Incorporated

INSM

68.29 USD

OPKO Health, Inc. logo

OPKO Health, Inc.

OPK

1.48 USD

Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

BEAM

23.3 USD

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

41.81 USD

Axonics, Inc. logo

Axonics, Inc.

AXNX

70.98 USD

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

1.18 USD

Arvinas, Inc. logo

Arvinas, Inc.

ARVN

17.22 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

51.66 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

2.77 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)